Ted Dawson

Ted Dawson
Name	Ted Dawson
Birth date	1950s
Birth place	United States
Fields	Neurology, Neurodegeneration, Clinical Research
Institutions	Johns Hopkins University School of Medicine; National Institute on Aging
Alma mater	Princeton University; Columbia University College of Physicians and Surgeons

Ted Dawson is an American physician-scientist and neurologist noted for pioneering work on neurodegenerative diseases, mitochondrial biology, and translational therapeutics. He has held leadership roles at major research centers and contributed to the mechanistic understanding of Parkinsonian syndromes, Huntington disease, and age-related neuronal loss. His career bridges basic science, clinical neurology, and institutional program building at prominent universities and federal institutes.

Early life and education

Born in the United States in the 1950s, Dawson completed undergraduate studies at Princeton University before attending the Columbia University College of Physicians and Surgeons for medical training. He subsequently pursued residency and fellowship training in neurology and neuropathology at leading academic centers, including programs affiliated with Johns Hopkins University School of Medicine and other major medical institutions. During his formative training he became involved with research groups studying cellular mechanisms of neuronal injury and the role of protein aggregation in human neurodegenerative disorders, interacting with investigators from the National Institutes of Health and collaborating laboratories in the United States.

Research and career

Dawson established a laboratory focusing on molecular pathways of neuronal death and survival, joining faculty ranks at Johns Hopkins University School of Medicine where he developed translational research programs linking bench discoveries to clinical applications. He has served in leadership at the National Institute on Aging and led collaborative consortia that included investigators from institutions such as Massachusetts General Hospital, Harvard Medical School, Columbia University, University of Pennsylvania, and other research hospitals. His research employed models ranging from cellular systems to transgenic rodent models used in studies at centers like the Jackson Laboratory and in multicenter preclinical consortia supported by the National Institutes of Health.

Throughout his career he has collaborated with scientists across disciplines, including biochemists, geneticists, and pharmacologists at organizations such as Genentech, Pfizer, and nonprofit foundations focused on neurodegeneration, and contributed to translational pipelines linking academic discovery to clinical trials run at sites including Johns Hopkins Hospital and regional trial networks. He has served on advisory boards and editorial boards of journals published by societies including the American Neurological Association and the Society for Neuroscience.

Major contributions and discoveries

Dawson’s laboratory made influential discoveries concerning programmed cell death pathways in neurons, including characterization of factors implicated in apoptosis and necroptosis relevant to disorders such as Parkinson's disease and Huntington's disease. His work elucidated roles for mitochondrial dysfunction, oxidative stress, and protein aggregation in neurodegeneration, intersecting with studies of proteins and pathways investigated by groups studying alpha-synuclein, parkin, LRRK2, tau protein, and huntingtin.

He contributed to defining the molecular interplay between poly(ADP-ribose) metabolism enzymes and neuronal death, identifying targets that modulate cell survival and may be amenable to therapeutic intervention. These findings linked biochemical pathways to pathological features observed in postmortem studies by neuropathologists at centers like the Mayo Clinic and the National Institute of Neurological Disorders and Stroke brain banks. Dawson’s team published influential papers on mechanisms of synaptic dysfunction and axonal degeneration that integrated genetics from consortia such as the Alzheimer's Disease Neuroimaging Initiative and population studies coordinated with the Framingham Heart Study and other longitudinal cohorts.

His translational efforts supported early-phase clinical development of small molecules and biologics aimed at modifying disease progression, collaborating with investigators running trials at institutions including Massachusetts General Hospital and networks such as the Alzheimer's Disease Cooperative Study.

Awards and honors

Over his career he received recognition from professional societies and research organizations, including awards and lectureships from the American Academy of Neurology, the American Neurological Association, and honors granted by universities and philanthropic foundations supporting neuroscience. He has been elected to leadership roles in committees organized by the National Institutes of Health and invited to deliver keynote addresses at meetings sponsored by the Society for Neuroscience, the Movement Disorder Society, and international congresses on neurodegeneration.

He has held endowed professorships and chaired departmental and institute-level initiatives at major medical centers, and received grant support from agencies such as the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, and private funders including disease-specific foundations.

Personal life and legacy

Dawson’s personal life has been integrated with his professional commitments to mentorship and program building; he trained numerous clinician-scientists who have taken faculty positions at institutions such as Johns Hopkins University School of Medicine, Columbia University, University of California, San Francisco, and Yale School of Medicine. His legacy includes a body of literature cited across fields of neurobiology, clinical neurology, and translational medicine, as well as institutional programs that continue research on mechanisms of neuronal death and therapeutic development. His contributions influenced subsequent work on therapeutic strategies pursued by academic investigators and industry partners focused on Parkinson's disease and related disorders.

Category:American neurologists Category:Physician-scientists Category:Neuroscientists